新诺威(300765) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was RMB 507.06 million, a decrease of 14.48% compared to the same period last year[2] - Net profit attributable to shareholders in Q3 2024 was RMB 2.30 million, a sharp decline of 98.03% year-over-year[2] - Total revenue for the first nine months of 2024 was RMB 1.48 billion, down 23.66% compared to the same period in 2023[2] - Basic earnings per share for Q3 2024 were RMB 0.0020, a decrease of 97.61% year-over-year[2] - Weighted average return on equity for Q3 2024 was 0.06%, down 2.49 percentage points compared to the same period last year[2] - Total operating income decreased to 1,478,923,011.81 yuan from 1,937,205,663.14 yuan, a decline of 23.7%[20] - Net profit attributable to parent company shareholders decreased to 139,329,413.32 yuan from 381,755,724.89 yuan, a decline of 63.5%[21] - Basic earnings per share decreased to 0.0995 yuan from 0.2738 yuan, a decline of 63.7%[21] - Total comprehensive income decreased to -46,983,781.56 yuan from 188,951,764.56 yuan, a decline of 124.9%[21] - Total operating costs decreased to 1,460,363,336.66 yuan from 1,663,779,097.25 yuan, a decline of 12.2%[20] - Income tax expense decreased to 65,606,355.63 yuan from 101,903,517.70 yuan, a decline of 35.6%[21] Cash Flow and Liquidity - Cash and cash equivalents decreased by 65.69% to RMB 1.29 billion as of September 30, 2024, due to large-term deposits, share repurchases, and R&D payments[6] - Operating cash flow for the first nine months of 2024 was negative RMB 955.58 million, a significant decline of 13,563.51% compared to the same period in 2023[2] - Operating cash flow decreased by 13,563.51% to -955.58 million yuan, primarily due to historical R&D payments by Jushi Biotech[9] - Investing cash flow decreased by 80.22% to -918.87 million yuan, mainly due to the purchase of large certificates of deposit and investment payments[9] - Financing cash flow decreased by 132.47% to -607.14 million yuan, primarily due to cash dividends and share repurchases[9] - Net increase in cash and cash equivalents decreased by 282.38% to -2,482.94 million yuan, mainly due to the purchase of large-term deposits, share repurchases, cash dividends, and R&D payments by Jushi Biotech[9] - Net cash flow from operating activities was -955,575,497.94 yuan, a significant decline from the previous period's -6,993,628.68 yuan[23] - Net cash flow from investing activities was -918,868,799.42 yuan, compared to -509,852,052.29 yuan in the previous period[23] - Net cash flow from financing activities was -607,138,248.40 yuan, a sharp contrast to the previous period's 1,869,614,031.82 yuan[24] - The net increase in cash and cash equivalents was -2,482,936,754.48 yuan, compared to 1,361,403,545.77 yuan in the previous period[24] - The ending balance of cash and cash equivalents was 1,287,253,553.48 yuan, down from 3,564,989,249.72 yuan in the previous period[24] - Cash received from tax refunds was 34,352,449.12 yuan, a decrease from 103,951,439.23 yuan in the previous period[23] - Cash paid for goods and services was 1,940,223,225.10 yuan, significantly higher than the previous period's 947,986,427.32 yuan[23] - Cash paid to employees was 196,033,464.29 yuan, a decrease from 217,185,381.31 yuan in the previous period[23] - Cash received from investments was 100,000,000.00 yuan, with no comparable figure in the previous period[23] R&D and Subsidiary Performance - R&D expenses for the subsidiary Jushi Biotech reached RMB 403.95 million in the first nine months of 2024, with a 48.40% increase in Q3 compared to Q3 2023[5] - Prepaid expenses increased by 95.83% to RMB 73.53 million, primarily due to increased R&D and engineering payments by Jushi Biotech[6] - Accounts payable decreased by 73.73% to RMB 332.17 million, mainly due to Jushi Biotech settling historical R&D payments[6] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 14,908[10] - Shijiazhuang Yiling Pharmaceutical Co., Ltd. holds 73.60% of the shares, totaling 1,033,744,394 shares[10] - Hong Kong Securities Clearing Company Limited holds 1.34% of the shares, totaling 18,862,864 shares[10] - Pan Yuhong holds 1.13% of the shares, totaling 15,900,000 shares[10] - Shijiazhuang Yiling Ou Yi Pharmaceutical Co., Ltd. holds 0.82% of the shares, totaling 11,587,212 shares[10] - The restricted shares of Shijiazhuang Yiling Pharmaceutical Co., Ltd. increased by 26,253,418 shares to a total of 157,520,510 shares, with the restriction set to be lifted on November 14, 2025[12][13] - Minority shareholders' equity increased to 934,812,050.05 yuan from 202,446,728.23 yuan, an increase of 361.6%[19] - Total equity decreased to 4,748,173,725.00 yuan from 5,483,270,450.43 yuan, a decline of 13.4%[19] Asset and Liability Changes - As of the end of Q3 2024, the company's monetary funds decreased to 1.29 billion RMB from 3.77 billion RMB at the beginning of the year[17] - Accounts receivable increased to 433.37 million RMB in Q3 2024 from 392.38 million RMB at the beginning of the year[17] - Inventory rose to 321.24 million RMB in Q3 2024 compared to 224.82 million RMB at the start of the year[17] - Fixed assets stood at 2.05 billion RMB in Q3 2024, slightly down from 2.08 billion RMB at the beginning of the year[17] - Construction in progress increased significantly to 421.60 million RMB in Q3 2024 from 228.71 million RMB at the start of the year[17] - Long-term equity investments decreased slightly to 264.22 million RMB in Q3 2024 from 267.07 million RMB at the beginning of the year[17] - Intangible assets were reported at 226.81 million RMB in Q3 2024, down from 231.59 million RMB at the start of the year[17] - Total assets decreased to 5,718,366,517.96 yuan from 7,472,208,452.03 yuan, a decline of 23.5%[18] - Total liabilities decreased to 970,192,792.96 yuan from 1,988,938,001.60 yuan, a decline of 51.2%[18] Acquisition and Fundraising Plans - The company plans to acquire 100% equity of Shiyao Baike through issuing shares and paying cash, with a transaction value of 7.6 billion RMB, where cash payment accounts for 10% and share issuance for 90%[15] - The issuance price for the acquisition is set at 20.95 RMB per share, not less than 80% of the average stock price in the 20 trading days prior to the pricing benchmark date[15] - The company intends to raise up to 1.78 billion RMB in supporting funds by issuing shares to no more than 35 qualified specific investors[15] Sales and Revenue - Sales revenue from goods and services received in cash was 1,349,883,416.06 yuan, a decrease compared to the previous period's 1,802,760,100.19 yuan[23]